Loading...

ADMA ADMA BIOLOGICS INC Earnings Reports 8-K Filing

DM B

DM

ADMA BIOLOGICS INC

(ADMA)

2026 8-K

Press Release Issued

Share Repurchase Agreement

Management Change

Financial Results Update

Credit Facilities

Share Repurchase Program

Product Expansion

Financial Results

Executive Compensation

Corporate Presentation

Director Appointment

Financial Results

New Auditor Engagement

Accounting Firm Resignation

Credit Facility Repayment

Financial Results Announcement

Promotion of Brad Tade

Annual Meeting of Stockholders

Corporate Presentation

Earnings Reports

Promotion of Kaitlin Kesten...

Corporate Presentation

Executive Compensation

Financial Results Announcement

Artificial Intelligence Pro...

Corporate Presentation

Earnings Reports

Credit Agreement with Ares ...

FDA Approval for Plasma Col...

Earnings Reports

Financial Results Announcement

Post-Market Surveillance

Director Vacancy

Financial Results Announcement

Amendment to Credit Agreeme...

Financial Results Announcement

Compensation and Director C...

FDA Approval for Plasma Col...

Earnings Reports

External Links:

On January 12, 2026, ADMA Biologics, Inc. announced preliminary, unaudited full-year revenue results for 2025, which are subject to change pending final audit. This filing is significant as it reflects ongoing business operations and future financial outlook for investors.

AI Assistant

ADMA BIOLOGICS INC

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.